The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin Marcus M. Schittenhelm,Kerstin M. Kampa,et al. Cell Cycle 15 August 2009;8:16, 2621-263
Daniel J. DeAngelo, et al. Blood. 2006 December 1;108(12): 3674–3681.
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.